develop
use
topic
microbicid
potenti
offer
addit
strategi
reduc
spread
human
immunodefici
viru
hiv
carbohydratebind
agent
cba
show
specif
high
mannos
carbohydr
surfac
heavili
glycosyl
envelop
hiv
endow
potent
antihiv
activ
fact
number
algal
lectin
cyanovirinn
microvirin
microcysti
viridi
lectin
scytovirin
oscillatoria
agardhii
agglutinin
griffithsin
consid
potenti
microbicid
candid
prevent
sexual
transmiss
hiv
topic
applic
inhibit
infect
cell
cellfre
viru
also
effici
prevent
viru
transmiss
virusinfect
cell
uninfect
target
tlymphocyt
dcsigndirect
captur
transmiss
lymphocyt
review
focus
structur
properti
carbohydr
specif
algal
lectin
antivir
activ
hiv
sever
envelop
virus
safeti
profil
viral
resist
pattern
sinc
discoveri
human
immunodefici
viru
hiv
almost
year
ago
million
peopl
kill
viru
approxim
million
peopl
estim
live
hiv
hiv
epidem
continu
larg
unab
approxim
new
infect
everi
day
exist
hiv
drug
treatment
control
abl
cure
hiv
infect
effect
approach
halt
epidem
establish
effect
prevent
method
multifacet
approach
incorpor
multipl
type
intervent
includ
behavior
modif
voluntari
counsel
hiv
test
condom
use
male
circumcis
diagnosi
treatment
std
vaccin
oral
preand
postexposur
prophylaxi
develop
antihiv
microbicid
vaccin
hiv
offer
best
chanc
reduc
hiv
infect
viral
transmiss
howev
approach
elicit
protect
immun
respons
remain
still
elus
preexposur
prophylaxi
oral
administ
antiretrovir
drug
protect
hivneg
person
may
prove
effect
substanti
concern
toxic
associ
longterm
exposur
risk
select
resist
viru
variant
topic
deliv
drug
appli
vagin
rectal
design
microbicid
offer
distinct
advantag
would
limit
toxic
associ
system
prophylaxi
enorm
advantag
microbicid
women
use
without
partner
know
although
condom
provid
excel
protect
hiv
sexual
transmit
diseas
women
alway
abl
negoti
condom
use
frequent
men
reluct
use
condom
regular
partner
impli
one
partner
unfaith
one
studi
estim
singl
microbicid
efficaci
could
prevent
one
million
new
infect
per
year
howev
signific
protect
yet
achiev
approach
till
one
antivir
compound
claim
activ
microbicid
gel
caprisa
trial
investig
gel
contain
tenofovir
gel
reduc
women
risk
hiv
infect
studi
particip
counsel
appli
two
gel
dose
h
first
dose
within
h
sex
second
dose
soon
possibl
within
h
sex
dose
regimen
voic
studi
howev
larg
phase
iib
clinic
trial
investig
tenofovir
gel
use
oncedaili
formul
unfortun
protect
effect
observ
last
decad
shift
develop
broadspectrum
microbicid
product
rel
nonspecif
mechan
antivir
action
surfact
antiretrovir
microbicid
target
specif
step
viral
life
cycl
hiv
entri
process
infect
target
cell
hiv
complex
multistag
process
involv
viral
attach
host
cell
subsequ
membran
fusion
hiv
enter
cell
via
interact
cellular
receptor
socal
hiv
coreceptor
insert
cellular
membran
membran
fusion
extern
transmembran
heavili
glycosyl
protein
present
virion
surfac
trimer
complex
approxim
half
total
molecular
mass
contribut
nlink
glycan
small
variabl
contribut
olink
glycan
nlink
glycan
attach
protein
backbon
posit
predetermin
short
amino
acid
motif
nxst
design
potenti
nglycosyl
site
png
nlink
glycan
ad
cotransl
newli
synthes
polypeptid
endoplasm
reticulum
er
link
amid
side
chain
asparagin
residu
present
sequon
nx
ts
x
amino
acid
except
prolin
nlink
glycan
assembl
high
mannos
type
glycan
design
glc
man
glcnac
membranebound
dolichyl
pyrophosph
precursor
er
addit
glycan
nativ
peptid
play
pivot
role
protein
fold
correctli
fold
protein
migrat
golgi
apparatu
glycosidas
glycosyltransferas
process
glycan
remov
trim
ad
new
sugar
creat
hybrid
complex
type
glycan
howev
number
nglycan
env
resist
mannos
trim
retain
oligomannos
composit
high
mannos
type
glycan
appear
cluster
envelop
result
unusu
densiti
glycan
envelop
high
number
high
mannos
type
glycan
peculiar
human
cell
rare
express
protein
carri
type
glycan
addit
carbohydr
moieti
act
shield
mask
neutralizationsensit
epitop
recognit
immun
system
howev
recent
broad
potent
neutral
antibodi
found
specif
highmannoseglycandepend
epitop
support
hypothesi
glycan
import
target
hiv
glycoprotein
broad
neutral
respons
vivo
provid
import
lead
futur
direct
develop
neutral
antibodybas
antihiv
vaccin
carbohydratebind
agent
cba
interact
glycan
viral
envelop
hiv
block
viral
entri
target
cell
algal
lectin
consid
cba
potent
antihiv
activ
describ
far
subject
review
lectin
protein
nonimmunoglobulin
natur
capabl
recognit
revers
bind
carbohydr
moieti
complex
glycocongug
without
alter
coval
structur
recogn
glycosyl
ligand
lectin
found
across
wide
varieti
differ
speci
natur
includ
prokaryot
sea
coral
alga
fungi
higher
plant
invertebr
vertebr
involv
mani
biolog
process
among
hostpathogen
interact
cellcel
commun
induct
apoptosi
cancer
metastasi
differenti
target
cell
well
recogn
bind
carbohydr
review
focu
algal
lectin
antivir
activ
gener
alga
refer
plantlik
organ
usual
photosynthet
aquat
true
root
stem
leav
vascular
tissu
simpl
reproduct
structur
major
group
alga
divis
cyanophyta
bluegreen
alga
chlorophyta
green
alga
cryptophyta
chrysophyta
goldenbrown
alga
pyrrophyta
dinoflagel
bacillariophyta
euglenophyta
rhodophyta
red
alga
member
divis
cyanophyta
bluegreen
alga
prokaryot
cell
organ
nucleu
mitochondria
chloroplast
member
algal
divis
eukaryot
recent
year
algal
lectin
could
inhibit
replic
hiv
mani
class
envelop
virus
interact
carbohydr
present
viral
envelop
discov
cyanovirinn
cvn
kda
protein
deriv
cyanobacterium
nostoc
ellipsosporum
given
far
attent
antivir
lectin
primari
structur
disulfid
bond
pattern
cvn
determin
convent
biochem
techniqu
cvn
consist
amino
acid
residu
divid
two
intern
repeat
amino
acid
show
strong
sequenc
similar
one
anoth
equival
posit
disulfid
bond
domain
form
residu
stabil
disulfid
bond
domain
b
consist
residu
one
disulfid
bond
figur
predomin
form
cvn
solut
monomer
form
cvn
contain
two
carbohydr
recognit
site
symmetr
oppos
domain
protein
crosslink
branch
oligomannosid
form
higher
order
structur
cvn
specif
recogn
man
link
mannos
substructur
arm
figur
f
microvirin
mvn
recent
discov
novel
lectin
isol
cyanobacterium
mycrocysti
aeruginosa
show
ident
amino
acid
level
cvn
mvn
averag
molecular
mass
kda
consist
amino
acid
amino
acid
sequenc
mvn
contain
two
tandem
repeat
residu
ident
sequenc
threedimension
structur
exhibit
cvn
famili
fold
mvn
monomer
solut
structur
mvn
includ
two
homolog
domain
domain
form
residu
stabil
two
disulfid
bond
domain
b
consist
residu
one
disulfid
bond
figur
mvn
contain
one
carbohydr
recognit
site
show
specif
man
disaccharid
unit
termin
arm
high
mannos
nlink
oligosaccharid
figur
microcysti
viridi
lectin
mvl
isol
cyanobacterium
microcysti
viridi
mvl
molecular
weight
kda
consist
amino
acid
figur
amino
acid
sequenc
mvl
contain
two
highli
homolog
domain
amino
acid
amino
acid
ident
domain
mvl
homodim
stabil
extens
intermolecular
interfac
monom
specif
mvl
uniqu
minim
target
compris
glcnac
tetrasaccharid
core
oligomannosid
figur
man
glcnac
bind
preform
cleft
distal
end
domain
mvl
manner
total
four
independ
carbohydr
molecul
associ
homodim
scytovirin
svn
kda
algal
lectin
isol
aqueou
extract
cultur
cyanobacterium
scytonema
varium
uniqu
protein
consist
singl
amino
acid
chain
highli
conserv
intern
repeat
residu
residu
ident
remain
three
maintain
similar
charact
one
significantli
differ
figur
amino
acid
sequenc
svn
contain
cystein
form
five
disulfid
bond
svn
strictli
monomer
indic
oligomer
condit
lectin
bind
specif
tetrasaccharid
substructur
high
mannos
oligosaccharid
man
tetrasaccharid
cyanobacteri
lectin
oscillatoria
agardhii
agglutinin
oaa
isol
oscillatoria
agardhii
strain
molecular
weight
kda
amino
acid
sequenc
oaa
consist
amino
acid
form
two
homolog
domain
consist
residu
sequenc
ident
figur
sato
et
al
report
oaa
recogn
long
carbohydr
sequenc
nonreduc
termin
mannos
reduc
termin
glcnac
residu
minim
length
pentasaccharid
figur
howev
koharudin
et
al
publish
oaa
preferenti
bind
man
observ
interact
protein
glcnac
disaccharid
fact
protein
contain
two
carbohydr
bind
site
posit
symmetr
two
end
group
report
bind
cleft
protein
short
accommod
tetrasaccharid
therefor
assum
oaa
recogn
mainli
either
two
man
disaccharid
unit
imbed
within
pentasaccharid
glycan
previous
describ
algal
lectin
isol
cyanobacteria
howev
also
one
lectin
describ
isol
red
alga
griffithsin
grft
isol
griffithsia
sp
collect
water
new
zealand
grft
molecular
weight
kda
sequenc
amino
acid
figur
residu
posit
match
standard
amino
acid
function
role
indistinct
grft
exist
exclus
kda
dimer
domainswap
structur
two
one
monom
combin
monom
form
prism
three
fourstrand
sheet
homodim
six
carbohydr
bind
pocket
locat
opposit
end
doublepr
homodim
grft
bind
oligomannos
glycan
target
termin
mannos
residu
found
algal
lectin
describ
possess
activ
howev
limit
data
avail
other
extens
studi
main
goal
give
summari
antihiv
activ
profil
compar
potenc
tabl
oaa
first
describ
sato
et
al
sinc
one
studi
evalu
antivir
activ
oaa
activ
cell
strain
iiib
ec
also
antihiv
activ
mvl
test
one
research
group
found
activ
potent
quantit
vaccinia
viru
report
gene
assay
ec
nm
antivir
activ
sever
lectin
investig
extens
hiv
simianhuman
immunodefici
viru
shiv
simian
immunodefici
viru
siv
laboratori
strain
clinic
isol
sever
cell
line
pbmc
macrophag
well
activ
envpseudotyp
hiv
isol
luciferas
report
gene
assay
tzmbl
cell
base
singleround
infect
tabl
cvn
activ
laboratori
strain
ec
valu
nm
cvn
also
test
clinic
isol
mani
differ
clade
found
activ
ec
valu
nm
cvn
found
activ
siv
tabl
mvn
activ
laboratori
strain
clinic
isol
ec
valu
nm
nm
howev
contrast
cvn
mvn
activ
clinic
isol
group
activ
found
laboratori
strain
clinic
isol
ec
nm
tabl
svn
activ
laboratori
strain
clinic
isol
ec
valu
nm
nm
respect
tabl
data
found
activ
siv
grft
potent
antihiv
algal
lectin
describ
far
activ
laboratori
strain
ec
valu
nm
grft
show
also
potent
antivir
activ
differ
clade
clinic
isol
ec
valu
nm
found
activ
siv
shiv
replic
assay
tabl
order
efficaci
microbicid
must
overcom
sever
challeng
impos
mucos
microenviron
intend
protect
complet
mechan
transmiss
femal
genit
tract
fulli
understood
multipl
pathway
propos
initi
infect
donor
cell
free
virion
trap
cervic
mucu
free
virion
may
penetr
thin
gap
squamou
epitheli
cell
cervicovagin
mucosa
epithelium
encount
langerhan
cell
lc
langerhan
cell
subtyp
dendrit
cell
dc
express
ctype
lectin
langerin
antigen
present
cell
form
tight
network
mucos
squamou
epithelium
cellular
process
reach
superfici
layer
epitheli
surfac
enabl
directli
bind
lc
becom
intern
cytoplasm
vesicl
also
propos
infect
lc
migrat
lymphoid
tissu
effici
transmit
cell
addit
cell
infiltr
vagin
ectocerv
squamou
epithelium
infect
viru
may
also
penetr
sever
layer
lumin
surfac
reach
suprabas
basal
epitheli
cell
suscept
trancytosi
infect
intern
virion
endocyt
compart
free
virion
hivinfect
donor
cell
also
penetr
vagin
epithelium
migrat
microabras
induc
intercours
mucos
stroma
hivinfect
donor
cell
taken
lymphat
venou
microvessel
transport
local
lymph
node
blood
circul
respect
penetr
free
virion
make
contact
dc
cell
macrophag
submucosa
cell
probabl
princip
cell
type
infect
portal
entri
suscept
target
cell
popul
vagina
ectoand
endocervix
larg
spatial
dispers
popul
lie
beneath
epithelium
lesser
extent
deeper
submucosa
also
cell
outnumb
macrophag
dendrit
cell
stromal
dc
express
dendrit
cellspecif
intercellular
adhes
nonintegrin
dcsign
low
amount
multipl
mechan
dc
augment
infect
cell
propos
classic
tran
infect
dcsign
act
receptor
effici
transfer
viru
lymphocyt
occur
across
infecti
synaps
zone
dctcell
contact
hostcel
receptor
concentr
altern
tran
infect
may
also
occur
associ
dcderiv
exosom
anoth
mechan
involv
transmiss
new
virion
product
infect
dc
across
infecti
synaps
cell
howev
clear
evid
describ
mode
viral
transmiss
dc
cell
genit
mucosa
still
lack
thu
ultim
goal
develop
effect
microbicid
inhibit
transmiss
cellfre
virus
figur
also
transmiss
donorhivinfect
cell
figur
hivinfect
cell
express
viral
glycoprotein
cell
surfac
lectin
abl
bind
inhibit
syncytium
format
infect
cell
uninfect
cell
algal
lectin
cvn
mvn
grft
report
inhibit
transmiss
hiv
persist
infect
cell
uninfect
cell
ic
valu
nm
nm
nm
respect
figur
algal
lectin
mvl
svn
oaa
knowledg
data
avail
test
oaa
potenti
inhibit
transmiss
hiv
persist
infect
cell
uninfect
cell
ic
valu
nm
besid
infect
cell
macrophag
cellfre
virion
donorinfect
cell
dcsigndirect
captur
transmiss
lymphocyt
consid
import
avenu
primari
infect
women
expos
sexual
intercours
figur
algal
lectin
mvl
oaa
knowledg
data
avail
potenti
microbicid
candid
cvn
grft
also
test
ex
vivo
cervic
explant
model
could
potent
inhibit
infect
model
grft
effect
prevent
infect
cvn
cervic
explant
tissu
also
spontan
migrat
dc
overnight
cultur
cvn
grft
could
inhibit
transfer
viru
migratori
cell
anoth
preclin
test
cvn
evalu
novel
penil
tissu
explant
model
cvn
confer
protect
similar
seen
cervic
explant
final
cvn
lectin
far
test
vivo
transmiss
model
vagin
macaqu
studi
gel
solut
contain
mgml
mgml
mgml
cvn
use
get
inhibit
vagin
shiv
challeng
also
cvn
protect
macaqu
rectal
shiv
challeng
recent
activ
lactobacillu
jensenii
express
cvn
test
vivo
macaqu
cervicovagin
mucosa
women
coat
bacteri
biofilm
includ
lactobacillu
commens
bacterium
role
maintain
healthi
mucosa
genet
engin
produc
antivir
peptid
lagenaur
et
al
report
reduct
transmiss
chimer
simianhiv
repeat
vagin
challeng
macaqu
treat
cvnexpress
lactobacillu
jensenii
infect
commonli
associ
sexual
transmit
virus
hsv
facilit
risk
hiv
acquisit
worsen
clinic
cours
hiv
diseas
therefor
would
benefici
futur
microbicid
effici
also
std
given
high
degre
similar
sever
envelop
virus
term
presenc
role
highmannos
glycan
envelop
glycoprotein
cba
approach
like
extend
envelop
virus
caus
variou
chronic
livethreaten
infect
human
mani
research
group
investig
antivir
activ
cvn
grft
differ
class
envelop
virus
cvn
effect
ebola
viru
influenza
b
hepat
c
viru
measl
viru
herp
simplex
viru
human
herp
viru
contrast
accord
public
cvn
inhibit
hepat
b
viru
cytomegaloviru
vaccinia
viru
adenoviru
type
contrast
mvn
ic
cvn
activ
envelop
virus
murin
leukemia
viru
vesicular
stomat
viru
grft
prevent
hepat
c
viru
infect
vitro
mitig
hepat
c
viru
infect
vivo
also
grft
display
low
nanomolar
activ
sarsrel
coronaviru
sarscov
fact
grft
activ
coronaviru
strain
util
proteinprotein
interact
viral
target
eg
cellular
receptor
sarscov
b
c
e
util
proteincarbohydr
interact
viral
attach
ie
sialic
acid
moieti
ibvcov
irrespect
potent
antivir
activ
lectin
potenti
microbicid
candid
safeti
issu
extrem
import
also
contribut
lack
efficaci
microbicid
spermicid
first
compound
test
profoundli
potenti
antihiv
microbicid
show
vitro
activ
sexual
transmit
infect
prevent
siv
infect
macaqu
howev
evalu
clinic
trial
fail
exert
protect
transmiss
women
even
wors
caus
toxic
side
effect
even
enhanc
infect
transmiss
longer
pursu
potenti
prevent
agent
microbicid
cellulos
sulfat
cs
found
safe
phase
safeti
studi
howev
phase
iii
clinic
trial
interrupt
preliminari
result
indic
increas
risk
hiv
transmissioninfect
cstreat
women
import
microbicid
agent
safe
effect
follow
vagin
rectal
administr
caus
minim
genit
side
effect
longterm
repeat
administr
buffa
et
al
publish
cvn
mitogen
activ
follow
day
exposur
lectin
associ
modest
increas
express
gamma
interferon
stromal
cellderiv
factor
interleukin
howev
h
exposur
cvn
effect
cytokin
express
pbmc
tissu
explant
cultur
h
period
suggest
potenti
inflamm
low
contrast
group
report
cvn
affect
cell
morpholog
pbmc
enhanc
express
cellular
activ
marker
hladr
day
incub
also
pbmc
activ
cvn
suscept
infect
cvn
exert
pronounc
mitogen
activ
significantli
enhanc
pbmc
product
wide
varieti
cytokin
mvn
comparison
cvn
much
better
safeti
profil
cell
pbmc
mvn
exert
cellular
toxic
dose
respect
sharp
contrast
cvn
cc
valu
cell
cemss
cell
pbmc
tzmbl
cell
nm
nm
mm
mm
respect
also
mvn
activ
pbmc
measur
cellular
activ
marker
howev
substanti
effect
pbmc
releas
sever
proinflammatori
cytokin
grft
measur
effect
cell
viabil
cc
cell
pbmc
significantli
upregul
describ
cd
marker
tcell
activ
also
treatment
grft
induc
minim
chang
secret
inflammatori
cytokin
chemokin
epitheli
cell
human
pbmc
addit
okeef
et
al
evalu
grft
rvi
assay
standard
test
safeti
vagin
topic
product
requir
us
food
drug
administr
found
grft
accept
safeti
profil
proceed
clinic
test
furthermor
grftp
plantproduc
grft
shown
safe
ex
vivo
human
cervic
explant
exposur
hiv
algal
lectin
eventu
result
resist
resist
virus
accumul
aminoacid
mutat
appear
mainli
put
nglycosyl
motif
either
asparagin
serin
threonin
lead
disrupt
glycosyl
site
current
limit
data
avail
resist
profil
algal
lectin
mvn
resist
viru
select
long
period
cell
cultur
passag
two
pure
amino
acid
mutat
amino
acid
present
wildtyp
viru
complet
disappear
detect
delet
glycan
posit
addit
two
mix
mutat
mixtur
origin
mutat
amino
acid
observ
affect
glycan
posit
comparison
cvn
resist
viru
select
cell
cultur
passag
two
pure
mutat
delet
glycan
posit
five
independ
cvnexpos
strain
select
total
eight
differ
amino
acid
mutat
exclus
locat
nglycosyl
site
envelop
surfac
observ
six
eight
mutat
result
delet
highmannos
type
nglycan
ie
amino
acid
posit
two
mutat
ie
posit
delet
complex
type
nglycan
variabl
domain
interestingli
singl
viru
strain
select
presenc
cvn
witvrouw
et
al
show
glycan
delet
n
posit
delet
due
delet
stretch
affect
glycosyl
site
time
hu
et
al
assess
specif
minim
requir
deglycosyl
cvn
resist
indic
highmannos
residu
correl
resist
level
singl
deglycosyl
sitedirect
mutagenesi
rang
primari
tcelllineadapt
isol
result
mark
resist
grft
maintain
sensit
cvn
addit
concomit
lack
glycan
posit
result
natur
resist
cvn
grft
svn
confirm
sitedirect
mutagenesi
viral
drug
resist
problem
use
microbicid
thu
high
genet
barrier
favor
microbicid
candid
howev
delet
part
glycan
shield
hiv
may
also
benefit
shown
presenc
glycan
envelop
hiv
crucial
import
evas
immunolog
surveil
host
cba
may
therefor
dual
mechan
action
firstli
direct
antivir
activ
bind
glycan
viral
envelop
secondli
antivir
action
indirect
result
progress
creation
delet
envelop
glycan
shield
therebi
trigger
immun
system
act
previous
hidden
immunogen
epitop
viral
envelop
algal
lectin
cvn
mvn
grft
mvl
svn
oaa
promis
candid
microbicid
prevent
hiv
transmiss
interact
glycan
hiv
howev
lectin
uniqu
properti
includ
number
carbohydr
recognit
site
specif
oligosaccharid
differ
may
account
differ
antivir
activ
overal
algal
lectin
broad
activ
howev
grft
exhibit
superior
antihiv
activ
oaa
mvl
least
activ
cvn
grft
studi
extens
show
also
antivir
activ
envelop
virus
benefit
usag
microbicid
infect
commonli
associ
sexual
transmit
virus
hsv
hcv
facilit
risk
hiv
acquisit
worsen
clinic
cours
hiv
diseas
irrespect
potent
antivir
activ
microbicid
candid
safeti
issu
extrem
import
also
contribut
lack
efficaci
use
cvn
safe
microbicid
rais
question
cvn
clearli
stimulatorymitogen
activ
induc
high
amount
larg
number
cytokin
contrast
grft
stimulatori
properti
togeth
broad
potent
antivir
activ
algal
lectin
stand
potenti
candid
microbicid
develop
recent
et
al
combin
grft
nucleotid
revers
transcriptas
inhibitor
tenofovir
hiv
coreceptor
antagonist
maraviroc
fusion
inhibitor
enfuvirtid
combin
synergist
clade
b
clade
c
isol
pbmc
cell
antivir
activ
safeti
import
howev
guarante
success
microbicid
microbicid
fulfil
high
expect
also
accept
easi
use
afford
howev
misconcept
protein
algal
lectin
expens
use
exampl
grft
produc
multigram
quantiti
extract
nicotiana
benthamiana
plant
transduct
tobacco
mosaic
viru
vector
express
grft
also
use
lactobacillu
jensenii
express
lectin
eg
cvn
reduc
cost
develop
microbicid
transform
vagin
microflora
live
bioshield
kind
microbicid
applic
may
userfriendli
hope
lectin
contribut
develop
effici
safe
afford
microbicid
